{"url_path":"/sec/cocp/8-k/2026-06-03/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-03","source_url":"https://www.sec.gov/Archives/edgar/data/1412486/0001493152-26-026965-index.html","accession_number":"0001493152-26-026965","cik":"0001412486","ticker":"COCP","issuer_name":"Cocrystal Pharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1412486/0001493152-26-026965-index.html","primary_entity_key":"0001412486","primary_entity_name":"Cocrystal Pharma, Inc."},"word_count":78,"has_tables":true,"body_markdown":"**Item\n9.01 Financial Statements and Exhibits.**\n\n \n\n**(d)\nExhibits**\n\n \n\nExhibit\n \nDescription\n\n99.1\n \n[Press Release dated June 3, 2026](ex99-1.htm)\n\n104\n \n\nCover\nPage Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.\n\n \n\n \n**Cocrystal\nPharma, Inc.**\n\n \n \n \n\nDate:\nJune 3, 2026\nBy:\n*/s/\nJames Martin*\n\n \nName:\nJames\nMartin\n\n \nTitle:\nChief\nFinancial Officer"}